NCT05006898已完成1 期
Synergistic Use of Pilocarpine-Brimonidine-Oxymetazoline to Control Presbyopia Symptoms
Optall Vision2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- Jaeger notation near uncorrected visual acuity change
研究概览
简要总结
Low dose compose to control presbyopia symptoms
详细描述
A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
盲法说明
While in office the care provider took a number out of a closed container. Number 1 was designated for the placebo; Number 2 was designated for the compound
入排标准
- 年龄范围
- 40 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Presbyopic
- •40 - 59 years
排除标准
- •Diabetics
- •Previous eye surgery
- •Previous eye disease
- •> 0.50 myopia
- •> 1.5 hyperopia or astigmatism
结局指标
主要结局
Jaeger notation near uncorrected visual acuity change
时间窗: 1 hour
Number of lines improved 1 hour after drug instillation
Comparison of PBO compound Jaeger notation improvement vs Pilocarpine or Brimonidine alone
时间窗: 1 hour
Number of lines improve comparing PBO compound vs Pilocarpine or Brimonidine
次要结局
未报告次要终点
研究者
Cesar Alejandro Sanchez Galeana
Principal Investigator
Optall Vision
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia SymptomsPresbyopiaNCT05006911Optall Vision11
Unknown
早期 1 期
Pilocarpine and Brimonidine in Patients With Monofocal LensesPseudophakiaPresbyopiaNCT03825081Massachusetts Eye and Ear Infirmary33
招募中
不适用
Myopia Control Combined PBM With Myopic Defocus Lens in ChildrenMyopia, ProgressiveNCT05756959Beijing Airdoc Technology Co., Ltd.304
已完成
3 期
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaPresbyopiaNCT06542497Ocuphire Pharma, Inc.569
终止
2 期
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)Vitreomacular TractionSubretinal EdemaNCT04300881Wagner Macula & Retina Center2